Cancer patients who were prescribed oxycodone at starting dose of 10 mg - 20 mg per day.
Conditions
Interventions
None listed
Sponsors
Japanese Society for Pharmaceutical Palliative Care and Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)No prior administration of opioid analgesia except tramadol. (2)Age of at least 20 yaers. (3)Patients who were administered oxycodone extended-release tablets at starting dose for 10 mg - 20mg. (4)All medications administered regularly during 2 weeks after starting oxycodone hydrochloride extended-release tablets were known. (5)Without nausea and vomiting (6)ECOG) performance status of 0 to 2
Exclusion criteria
Exclusion criteria: (1)Patients who were titrated with oxycodone immediate-release preparations more than 1 day before starting oxycodone hydrochloride extended-release tablets (2)Patients with symptomatic brain metastases or clinically confirmed brain metastases during the evaluation period (3)Patients who administered cytotoxic anticancer drug or molecular targetting drug during the evaluation period from 1 week before the start of extended-release oxycodone tablets (4)Patients had received radiotherapy to the head, abdomen, or pelvis within 6 days before and during the evaluation period. (5)Patients with electrolyte abnormalities at the starting or around the start of oxycodone extended release tablets.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total number of concomitant medications which are CYP3A4 inhibitor and CYP3A4 substrate. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Total number of concomitant medications which are CYP3A4 inhibitor, CYP3A4 substrate, CYP2D6 inhibitor and CYP2D6 substrate. (2)Risk factor of discontinuing oxycodone, reducing dose or changing to other analgesia due to adverse effect (3)Risk factor of nausea or vomiting | — |
Countries
Japan
Contacts
Public ContactKatsuya Makihara
Yodogawa Christian Hospital Department of Pharmacy
Outcome results
None listed